vimarsana.com

Page 2 - சமூகம் க்கு ஆராய்ச்சி ஆன் நிகோடின் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NIH awards Marshall University professor $1 8 million for nicotine addiction research

 E-Mail IMAGE: Brandon J. Henderson, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has been awarded a $1.86 million Research Project Grant (R01). view more  Credit: Marshall University Joan C. Edwards School of Medicine HUNTINGTON, W.Va. - Brandon J. Henderson, Ph.D., an assistant professor of biomedical sciences at the Marshall University Joan C. Edwards School of Medicine, has been awarded a Research Project Grant (R01), one of the most competitive grants issued by the National Institutes of Health (NIH). Henderson was awarded the $1.86 million five-year grant (R01DA050717) from the National Institute on Drug Abuse to study the neurobiological and neurophysiological changes that occur due to vaping nicotine in flavored products. Henderson s research team is working to better understand how electronic nicotine delivery systems, or vaping, alter neurobiology to trigger nicotine addiction in adolescent

Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update

Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.

Achieve Life Sciences, Inc : Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update

(2) SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program. Recent Events & Highlights Initiated the Phase 3 ORCA-2 clinical trial evaluating the efficacy and safety of 3 mg cytisinicline dosed 3 times daily compared to placebo in 750 adult smokers at 15 clinical sites in the United States Presented data on smoker and e-cigarette user attitudes and perceptions on quitting at the Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting on February 24, 2021

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.